Conditional disease‐free survival after curative‐intent liver resection for neuroendocrine liver metastasis

2019 ◽  
Vol 120 (7) ◽  
pp. 1087-1095 ◽  
Author(s):  
Kota Sahara ◽  
Katiuscha Merath ◽  
Diamantis I. Tsilimigras ◽  
J. Madison Hyer ◽  
Alfredo Guglielmi ◽  
...  
Keyword(s):  
Liver Resection ◽  
Liver Metastasis ◽  
Disease Free Survival ◽  
Curative Intent ◽  
Free Survival ◽  
Neuroendocrine Liver Metastasis ◽  
Disease Free

scholarly journals The Impact of Sarcopenia on Overall and Disease-free Survival after Liver Resection for Colorectal Liver Metastasis

HPB ◽  
2021 ◽  
Vol 23 ◽  
pp. S735
Author(s):  
C.F. Fernández Mancilla ◽  
R. Rumenova Smilevska ◽  
B. Madrid Baños ◽  
J. Aparicio Navarro ◽  
M. Pujante Menchon ◽  
...  
Keyword(s):  
Liver Resection ◽  
Liver Metastasis ◽  
Colorectal Liver Metastasis ◽  
Disease Free Survival ◽  
Free Survival ◽  
The Impact ◽  
Disease Free

Surgery of colorectal metastasis in the Optimox 1 study. A GERCOR Study

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 3522-3522 ◽  
Author(s):  
N. Perez-Staub ◽  
G. Lledo ◽  
F. Paye ◽  
B. Gayet ◽  
M. Flesch ◽  
...  
Keyword(s):  
Median Overall Survival ◽  
Response Rate ◽  
Disease Free Survival ◽  
Complete Response ◽  
Additional Benefit ◽  
Curative Intent ◽  
Free Survival ◽  
Before And After ◽  
Unresectable Metastasis ◽  
Disease Free

3522 Background: Surgery of metastasis can cure arround 20% of metastatic colorectal cancer (MCRC) patients. The Optimox 1 study achieved a response rate over 50% with FOLFOX therapy in patients (pts) with initially unresectable metastasis which allowed to perform surgery in a significant number of pts (JCO 2006). We report here the results in pts who underwent surgery of metastasis (met). Methods: From jan 2000 to june 2002, 620 previously untreated patients with unresectable metastasis were randomized between FOLFOX4 every two weeks until progression (arm A), or FOLFOX7 for 6 cycles, maintenance without oxaliplatin for 12 cycles and reintroduction of FOLFOX7 (arm B). 101 pts were resected with a curative intent, 57 in arm A and 45 in arm B. Results: Patients characteristics were (arm A/B %): metachronous metastasis 77/51, liver met 82/91, lung met 16/11, other met 7/4, PAL < 3 ULN: 98/97, normal LDH: 52/51. 8% of pts achieved a complete response, 72% a partial response, 16% a stable disease. 89 pts had a single resection, 12 had a two-stage surgery. One patient died in arm B. Eleven pts who relapsed had a second surgery. Resection was radical (R0) for 71 pts (43 in arm A and 28 in arm B), 15 were R1 (margin invasion) and 15 were R2. R0/R1 patients had a median overall survival (OS) of 51 mo in arm A and 38 mo in arm B. Median disease-free survival (DFS) since surgery was 12 mo in arm A and 9 mo in arm B, with no statistical difference. 32% of R0/R1 pts were alive with no progression at 3 years in arm A and 20% in arm B. Median time from randomization to surgery was 8 mo. No difference was found between patients resected before 8 mo (n = 50) and after (n = 37) in OS (39 vs 45 mo, p = .67) nor in DFS (11.6 vs 9.5 mo, p = .24). Neither in pts resected before and after 6 mo in OS (p = .77) and DFS (p = .44). Conclusions: FOLFOX treatment allowed 14 % of unresectable patients to be rescued by surgery. There was no additional benefit to perform surgery after 6 months of therapy compared to early surgery. [Table: see text]

Impact of the third and subsequent lines of chemotherapy in the cure rate of patients with high-risk gestational trophoblastic neoplasia (HR-GTN).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e15521-e15521
Author(s):  
Gustavo Jankilevich ◽  
Maria Ines Bianconi ◽  
Silvina Otero ◽  
Lucia Alvarez ◽  
Claudio Storino
Keyword(s):  
Medical Records ◽  
Disease Free Survival ◽  
Gestational Trophoblastic Disease ◽  
Cure Rate ◽  
Curative Intent ◽  
Free Survival ◽  
The Third ◽  
Trophoblastic Disease ◽  
Disease Free ◽  
Line Chemotherapy

e15521 Background: Successful chemotherapy is the backbone of the treatment of patients with HR-GTN. However a percentage of this patients will recur to first treatment attempt. It is not defined how many lines of chemotherapy are required to achieve complete reponse and wether to continue with different chemotherapy regimens is beneficial for achieving the cure. Methods: We performed a review of medical records of consecutive patients with diagnosis of gestational trophoblastic disease (GTD) and HR-GTN by FIGO-OMS criteria between 1990-2011. All were treated in our hospital. Results: 365 patients were registrated with GTD diagnosis. Thirty-four patients had HRNTG, 23 patients (67.6%) had complete reponse with first and second line chemotherapy (EMA PE and EMA CO). Eight of eleven patients had complete reponse with additional regimens. Three patients died, one due toxicity. The reponse rate of third and more lines was 72%. Overall disease free survival was 91%. Conclusions: In patients with HRNTG three or more lines of treatment achieves the cure in a high percentage of patients. In this setting the therapy should always be with curative intent, regardless of the number of lines required to achieve this objective.

Gastric cancer liver metastasis: Optimal management for oligo-metastatic disease.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 136-136 ◽  
Author(s):  
Hiromichi Ito ◽  
Nobuyuki Takemura ◽  
Yoshihiro Ono ◽  
Takafumi Sato ◽  
Yoshihiro Mise ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Liver Resection ◽  
Liver Metastasis ◽  
Medical Records ◽  
Optimal Management ◽  
Curative Intent ◽  
Entire Cohort ◽  
Disease Free

136 Background: The role of surgery for gastric cancer liver metastasis (GCLM) has not been established and particularly, the optimal management for liver-isolated, oligo-GCLMs remains controversial. The aims of this study were to review the outcomes for our patients with GCLM who underwent liver resection and to define the optimal selection criteria for resection. Methods: The medical records of patients who underwent liver resection for GCLMs with curative intent at our institution from 1993 through 2018 were reviewed. Our criteria for liver resection included absence of extrahepatic disease, and the limited number of liver metastasis (often 3 or less). Results: Total 101 patients with GCLM (77 men [76%], median age 66 years) were included. Forty-seven patients (46%) had synchronous metastasis and all underwent simultaneous resection with the primary disease. Those with synchronous disease received neoadjuvant therapy more often than those with metachronous disease (63% vs 37%, p = 0.021). Median RFS and OS for the entire cohort were 11 months and 39 months, respectively, and 5-year-OS rate was 41%. Of note, 25 patients achieved survival longer than 5 years without any recurrence thereafter with median follow-up of 137 months. In the multivariate analyses, elevated CEA 50 ng/ml or greater and nodal status of the primary were associated with shorter RFS, while primary T4 disease, liver tumor 5cm or great and elevated CEA were associated with shorter OS (Table 1). Conclusions: For well selected patients with GCLM, liver resection is an effective therapy not only to prolong disease-free time, but also to achieve cure. CEA is useful to select patients with GCLM who unlikely benefit from aggressive surgery. [Table: see text]

Disease-free survival for 9 years after liver resection for stage IV gallbladder cancer: Report of a case

Surgery Today ◽  
1995 ◽  
Vol 25 (8) ◽  
pp. 750-753 ◽  
Author(s):  
Masayuki Yamamoto ◽  
Kazuo Miura ◽  
Masakazu Yoshioka ◽  
Yoshiro Matsumoto
Keyword(s):  
Liver Resection ◽  
Gallbladder Cancer ◽  
Disease Free Survival ◽  
Stage Iv ◽  
Free Survival ◽  
Disease Free

scholarly journals Posttreatment Surveillance in Patients with Prolonged Disease-Free Survival After Resection of Colorectal Liver Metastasis

2016 ◽  
Vol 23 (12) ◽  
pp. 3999-4007 ◽  
Author(s):  
Boris Galjart ◽  
Eric P. van der Stok ◽  
Joost Rothbarth ◽  
Dirk J. Grünhagen ◽  
Cornelis Verhoef
Keyword(s):  
Liver Metastasis ◽  
Colorectal Liver Metastasis ◽  
Disease Free Survival ◽  
Free Survival ◽  
Disease Free

PTH-104 Tumour doubling time of colorectal metastases in patients selected for liver resection does not influence post-operative disease-free survival

Gut ◽  
2015 ◽  
Vol 64 (Suppl 1) ◽  
pp. A454.1-A454
Author(s):  
M Wiggans ◽  
G Shahtahmassebi ◽  
S Aroori ◽  
M Bowles ◽  
C Briggs ◽  
...  
Keyword(s):  
Liver Resection ◽  
Doubling Time ◽  
Disease Free Survival ◽  
Colorectal Metastases ◽  
Free Survival ◽  
Tumour Doubling Time ◽  
Disease Free
Sign in / Sign up

Export Citation Format

Share Document